Eps8 (Epidermal Growth Factor Receptor Pathway Substrate 8)

Epidermal growth factor receptor pathway substrate 8 (Eps8) is an adaptor protein and can be phosphorylated by several receptor tyrosine kinases including EGFR and Src (1,2). Eps8 is composed of an N-terminal PTB domain, followed by an SH3 domain and a C-terminal effector domain. Eps8 controls actin-based motility by capping the barbed end of actin and bundling actin subunits through its C-terminal effector domain (3,4). The C-terminal alpha hexlical structure of Eps8 interacts directly with actin to exert these capping and bundling functions (5). The actin capping activity requires the release of Eps8 autoinhibitory binding through SH3 domain interaction with an adaptor molecule, such as Abi-1 (6). This SH3 domain of Eps8 also binds to RN-tre to regulate the down stream Rab5-mediated endocytosis pathway (6). Eps8 functions by binding several receptor tyrosine kinases, such as EGFR or FGFR, to enhance receptor mediated mitogenic Rac signaling and Rab5 endocytosis (6,7). The effector region of Eps8 is necessary for this process. By association with Abi-1 and forming the Eps8/Abi-1/Sos-1 complex, Eps8 couples initial growth factor stimulation to actin motility and the Rac activation pathway (8,9). Eps8 has been shown to be important in the cellular function of filopodial protrusions, cell migration, microvilli formation, and focal adhesion (10-13). Research studies have demonstrated that through its involvement in actin related cellular functions, Eps8 plays a role in cancer cell growth, survival, motility, and invasiveness (14-18).\n\nApplications: \nSuitable for use in Western Blot and Immunoprecipitation. Other applications not tested.\n\nRecommended Dilution:\nWestern Blot: 1:1000. Incubate membrane with diluted antibody in 5% w/v nonfat dry\nmilk, 1X TBS, 0.1% Tween-20 at 4 degrees C with gentle shaking, overnight.\nImmunoprecipitation: 1:100\nOptimal dilutions to be determined by the researcher.\n\nStorage and Stability:\nMay be stored at 4 degrees C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20 degrees C. Aliquots are stable for 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

137432

Size

100ul

Applications

IP, WB

Reactivities

Hum

Form

Supplied as a liquid in 10mM sodium HEPES, pH 7.5, 150mM NaCl, 100ug/ml BSA and 50% glycerol.

P Type

Pab

Purity

Purified by Protein A affinity chromatography.

Isotype

IgG

References

1. Fazioli, F. et al. (1993) EMBO J 12, 3799-808. 2. Gallo, R. et al. (1997) Oncogene 15, 1929-36. 3. Disanza, A. et al. (2004) Nat Cell Biol 6, 1180-8. 4. Disanza, A. et al. (2006) Nat Cell Biol 8, 1337-47. 5. Hertzog, M. et al. (2010) PLoS Biol 8, e1000387. 6. Lanzetti, L. et al. (2000) Nature 408, 374-7. 7. Auciello, G. et al. (2013) J Cell Sci 126, 613-24. 8. Scita, G. et al. (1999) Nature 401, 290-3. 9. Innocenti, M. et al. (2003) J Cell Biol 160, 17-23. 10. Welsch, T. et al. (2007) Cancer Lett 255, 205-18. 11. Frittoli, E. et al. (2011) Immunity 35, 388-99. 12. Zwaenepoel, I. et al. (2012) Mol Biol Cell 23, 1080-94. 13. Maa, M.C. et al. (2007) J Biol Chem 282, 19399-409. 14. Xu, M. et al. (2009) Endocrinology 150, 2064-71. 15. Chen, Y.J. et al. (2008) Mol Cancer Ther 7, 1376-85. 16. Yap, L.F. et al. (2009) Oncogene 28, 2524-34. 17. Chen, H. et al. (2010) Cancer Res 70, 9979-90. 18. Funato, Y. et al. (2004) Cancer Res 64, 5237-44.

Additional Info

Recognizes endogenous levels of total human Eps8 (both p97 long isoform and p68 short isoform).